NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference…
Category: Business
BTIG to Host 5th Annual Ophthalmology Day on December 1, 2025
NEW YORK–(BUSINESS WIRE)–BTIG announced today that its 5th Annual Ophthalmology Day will take place on Monday, December 1, 2025. The virtual, one-day event will include thematic panel discussions and one-on-one meetings. The event will be hosted by: …
AGCバイオロジクス、遺伝性網膜疾患向けにAAVantgardeのデュアルベクター遺伝子治療薬を製造へ
ミラン–(BUSINESS WIRE)–（ビジネスワイヤ） — AGCバイオロジクスは、AAVantgardeによるシリーズB資金調達ラウンドの完了直後も、同バイオテクノロジー企業との新たな製造契約を発表しました。これは、アデノ随伴ウイルス市場におけるAGCバイオロジクスの最新の進展となります。本契約の下、同社は、現在承認された治療法が存在せず、進行性かつ不可逆的な視力低下に対応するために設計されたAAVantgardeの2つの新規候補品について、Good Manufacturing Prac…
AGC Biologics produziert die Dual-Vektor-Gentherapien von AAVantgarde für erbliche Netzhauterkrankungen
MAILAND–(BUSINESS WIRE)–Nach dem Abschluss einer Serie-B-Finanzierungsrunde durch AAVantgarde hat AGC Biologics eine neue Produktionsvereinbarung mit dem Biotechnologieunternehmen bekannt gegeben. Damit hat AGC Biologics einen weiteren Meilenstein au…
AGC Biologics produrrà terapie geniche a doppio vettore di AAVantgarde mirate alle retinopatie ereditarie
MILANO–(BUSINESS WIRE)–Dopo la chiusura di un round di finanziamento di serie B da parte di AAVantgarde, AGC Biologics ha annunciato un nuovo accordo di produzione con l’azienda biotech, che rappresenta il progresso più recente di AGC Biologics nel m…
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders
MILAN–(BUSINESS WIRE)– #Biotech–On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated v…
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
WHIPPANY, N.J.–(BUSINESS WIRE)–U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous NSCLC
National Vision Holdings, Inc. Details Transformation Strategy and Long-Term Financial Objectives Underpinning Bold Reinvention
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will host an Investor Day at NASDAQ MarketSite in New York City today to detail its comprehensive transformation strategy and financial outl…
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event …
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA–(BUSINESS WIRE)–Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA–(BUSINESS WIRE)–Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
National Vision Holdings, Inc. to Host Investor Day November 17, 2025
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”), will host an Investor Day on Monday, November 17, 2025, in New York City, as previously announced. The event, to be held at the NASDAQ Mark…
Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company (“STAAR” or the…
Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collabo…
STAAR Surgical Announces Amendments to Alcon Merger Agreement
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the Company has agreed with Alcon I…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Com…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Com…
Two Global Leaders in Eyesight Restoration, Advancing Sight Network and Miracles In Sight, Announce Merger
BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today jointly announced the merger of the two organizations, which will begin operating as one on January 1, 2026. Globally, at least 253 million people l…
Two Global Leaders in Eyesight Restoration, Advancing Sight Network and Miracles In Sight, Announce Merger
BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today jointly announced the merger of the two organizations, which will begin operating as one on January 1, 2026. Globally, at least 253 million people l…
DefEYE, Inc. Announces Investment from ExSight Ventures
NEW YORK–(BUSINESS WIRE)–ExSight Ventures, a leading venture capital firm focused on transformational eye care innovations, today announced its investment in DefEYE, Inc., a rapidly growing ocular company developing decellularized placental-based tis…